Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

Rene WesthovensDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium;Rheumatology, University Hospitals Leuven, Leuven, BelgiumCorrespondence[email protected]
View further author information

Isabelle RavelingienDepartment of Rheumatology, Onze-Lieve-Vrouw Ziekenhuis Aalst, Asse, Aalst, BelgiumView further author information

Klaas VandevyvereReumakliniek MedSeen, Houthulst, BelgiumView further author information

Ingrid PansarUCB Pharma, Brussels, BelgiumView further author information

Oana PurcaruUCB Pharma, Brussels, BelgiumView further author information

Thomas KumkeUCB Pharma, Monheim am Rhein, GermanyView further author information

Lieve GyselbrechtAlgemeen Stedelijk Ziekenhuis, Aalst, BelgiumView further author information

show all

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date